A panel of experts review three clinical cases of hepatocellular carcinoma, highlighting individualized treatment approaches and key clinical trial data used to guide therapy.
November 24th 2021
Expert perspectives on the case of a 70-year-old man who presents and is diagnosed with solitary hepatocellular carcinoma measuring greater than 3cm.
December 10th 2021
Centered on the patient case of solitary hepatocellular carcinoma, panelists consider the combination of locoregional and systemic therapies to improve outcomes.
Shared insight on the results of the LEGACY study, which utilized Y90 transarterial radioembolization for patients with unresectable hepatocellular carcinoma.
Panelists discuss real-world experience with Y90 transarterial radioembolization for patients with unresectable hepatocellular carcinoma and highlight practical advice.
Moving on to the second case, the panel reviews optimal treatment strategies for a 74-year-old woman with solitary hepatocellular carcinoma <3 cm and a history of cirrhosis
January 3rd 2022
After introducing the third case, a patient with metastatic hepatocellular carcinoma, experts share their perspectives on the optimal diagnosis and work-up of advanced disease.
In the context of metastatic hepatocellular carcinoma, panelists reflect on the value of multidisciplinary care at their institutions.
Taking recent clinical trial data into account, panelists consider the best treatment option for a patient with metastatic hepatocellular carcinoma.
A brief discussion on the potential role for adjuvant therapy in patients with hepatocellular carcinoma.
A panel of experts review data from the IMbrave150 trial of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma and consider implications for treatment.